Merck & Co., Inc: Osteoporosis trials

The registry lists 22 Osteoporosis studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 8Phase 2 4Phase 3 6No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)TerminatedNCT01803607Phase 3Results posted
• A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)TerminatedNCT01630616Phase 1Results posted
• A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)CompletedNCT01120600Phase 3Results posted
• Safety and Tolerability of Odanacatib (0822-059)CompletedNCT01068262Phase 1Results posted
• MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)CompletedNCT00996801Phase 2Results posted
• A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)TerminatedNCT00960934Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)CompletedNCT00885170Phase 2Results posted
• Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)CompletedNCT00729183Phase 3Results posted
• A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)CompletedNCT00112437Phase 2Results posted
• Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)WithdrawnNCT01552122Phase 3
• Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)CompletedNCT01011725Phase 1
• A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy VolunteersCompletedNCT00863590Phase 1
• A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)CompletedNCT00863525Phase 1
• A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)CompletedNCT00770159Phase 1
• Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)CompletedNCT00769418Phase 1
• A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal WomenCompletedNCT00709540Phase 1
• Upper GI Handling of Branded vs. Generic AlendronateCompletedNCT00400530Phase 3
• Comparison of Osteoporosis Disease Management Strategies (0000-039)CompletedNCT00145080Not applicable
• Osteoporosis Disease Management Demonstration Project (0000-040)CompletedNCT00145067Not applicable
• Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)CompletedNCT00139438Not applicable
• Osteoporosis Disease Management Demonstration Project (0000-037)CompletedNCT00139425Not applicable
• A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)CompletedNCT00092079Phase 3